STOCK TITAN

CG Oncology director Leonard E. Post sells $92K

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

CG Oncology, Inc. director Leonard E. Post exercised options for 1,000 shares at $0.60 per share on November 16, 2026, acquired 1,000 common shares and sold 1,000 common shares at $92 per share. The sale was made under a Rule 10b5-1 trading plan adopted March 5, 2026. The reported post-exercise position in Director Stock Options was 101,077 underlying shares.

Insider POST LEONARD E
Role Director
Sold 1,000 shs ($92K)
Approx. gross sale proceeds $92K
Approx. exercise cost $600.00
Approx. pre-tax spread $91K
Type Security Shares Price Value
Exercise Director Stock Option (right to buy) F2 1,000 $0.00 $0.00
Exercise Common Stock 1,000 $0.60 $600.00
Sale Common Stock F1 1,000 $92.00 $92K
Holdings After Transaction: Director Stock Option (right to buy) — 101,077 options (Direct); Common Stock — 1,000 shares (Direct)
Footnotes (2)
  1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
  2. F2. Fully vested
Director Stock Option shares exercised 1,000 shares November 16, 2026
Option exercise price $0.60 per share November 16, 2026
Common shares acquired 1,000 shares November 16, 2026
Common shares sold 1,000 shares November 16, 2026
Sale price $92 per share November 16, 2026
Director Stock Option position after exercise 101,077 underlying shares Reported after the November 16, 2026 exercise
Rule 10b5-1 trading plan regulatory
"sale under a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CGON shares did Leonard E. Post sell and at what price?

Leonard E. Post sold 1,000 common shares at $92 per share on November 16, 2026. The sale was made under a Rule 10b5-1 trading plan adopted March 5, 2026.

What CGON options did Leonard E. Post exercise?

Post exercised options for 1,000 shares at $0.60 per share on November 16, 2026. The options were fully vested, and the reported post-transaction position in Director Stock Options was 101,077 underlying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
POST LEONARD E

(Last)(First)(Middle)
C/O CG ONCOLOGY, INC.
3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)
DALLAS TEXAS 75247

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M1,000A$0.61,000D
Common Stock11/16/2026S(1)1,000D$921,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (right to buy)$0.611/16/2026M1,000 (2)07/08/2028Common Stock1,000$0101,077D
Explanation of Responses:
1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
2. Fully vested
/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading